Inflarx (NASDAQ:IFRX) Downgraded by Zacks Investment Research to Sell

Inflarx (NASDAQ:IFRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

Several other research analysts have also recently commented on IFRX. JPMorgan Chase & Co. cut Inflarx from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $67.00 to $9.00 in a research note on Wednesday, June 5th. Raymond James reissued a “hold” rating on shares of Inflarx in a report on Friday, July 19th. Guggenheim lowered Inflarx from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $65.00 to $6.00 in a report on Wednesday, June 5th. Robert W. Baird lowered Inflarx from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $58.00 to $6.00 in a report on Wednesday, June 5th. Finally, Leerink Swann lowered Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $15.66.

Shares of NASDAQ:IFRX traded down $0.02 during trading on Thursday, hitting $2.56. The company’s stock had a trading volume of 596,450 shares, compared to its average volume of 860,805. Inflarx has a fifty-two week low of $2.45 and a fifty-two week high of $53.10. The stock’s 50-day moving average price is $3.02 and its two-hundred day moving average price is $26.89. The company has a market capitalization of $68.55 million, a PE ratio of -1.83 and a beta of -1.53.

Inflarx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, May 23rd. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.19. Equities research analysts forecast that Inflarx will post -2.09 EPS for the current year.

A number of institutional investors have recently made changes to their positions in IFRX. FNY Investment Advisers LLC bought a new stake in Inflarx in the second quarter valued at about $884,000. Morgan Stanley increased its holdings in Inflarx by 454.5% in the second quarter. Morgan Stanley now owns 337,247 shares of the company’s stock valued at $1,066,000 after buying an additional 276,424 shares during the last quarter. FMR LLC bought a new stake in Inflarx in the first quarter valued at about $9,609,000. Redmile Group LLC increased its holdings in Inflarx by 7.2% in the first quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock valued at $82,482,000 after buying an additional 147,238 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Inflarx during the second quarter valued at approximately $445,000. 57.02% of the stock is owned by hedge funds and other institutional investors.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Article: Short Selling

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.